AbelZeta Pharma, a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that clinical data from the first-in-human Phase I trial (NCT06249438) of C-CAR168 in patients with refractory autoimmune diseases will be presented as a late-breaking poster presentation at American College of Rheumatology (ACR) Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois, USA.
C-CAR168 is a 2nd Generation Bispecific CAR-T Targeting CD20 and BCMA
C-CAR168 is an autologous anti-CD20/BCMA bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy designed to simultaneously target autoantibody-producing plasma cells and their B-cell precursors, aiming to achieve “immune reset”.
In earlier results, presented at the 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), held in Toronto, Canada, May 21-24, 2025, C-CAR168 shows promising efficacy in highly refractory Lupus Nephritis, with reductions in proteinuria, preserved renal function, and improvements in laboratory and extrarenal features of Lupus Nephritis, enabling withdrawal of Immunosuppressants.
Robust PK/PD profile, excellent safety, and efficacy signals in a Secondary Progressive Multiple Sclerosis (SPMS) patients
Continued studies in China are expected to enroll more patients with Lupus Nephritis and/or Systemic Lupus Erythematosus, progressive Multiple Sclerosis, and indications such as Neuromyelitis Optica Spectrum Disorders and Systemic Sclerosis, to explore and confirm the clinical utility of C-CAR168 across a variety of autoimmune and neurological diseases.
__
Clinical trials
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (CAR-AID) – ClinicalTrials.gov ID NCT06249438
Reference
Shen N, Ding H, Li W, Shen Y, Zhang C, Ye Y, Wang R, Yang S,Chunmei Wu C, Dai Dai D, Chengxiao Zheng C, Yuan Qian Y, Luo X, Trinh T, Zhu J, Huang J, Yao Y. Clinical Impact of C-CAR168, a Novel AntiCD20/BCMA Composite Autologous CAR-T Therapy, in Refractory Lupus Nephritis. Abstract ID: #730. Presented at 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), Toronto, Canada, May 21-24, 2025 [Presentation]
Featured image: Licensed under the Unsplash+ License. Used with permission.
DOI
